Inducible ligand for α1β1 integrin and uses

Details Inducible ligand for α1β1 integrin and uses Inducible ligand for α1β1 integrin and uses

2008-02-08

2010-02-16

Haddad, Maher M (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388230, C530S388240

Reexamination Certificate

active

07662382

ABSTRACT:
The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.

REFERENCES:
patent: 5567440 (1996-10-01), Hubbell et al.
patent: 5788966 (1998-08-01), Chess et al.
patent: 6492325 (2002-12-01), Cosgrove
patent: 6955810 (2005-10-01), Gotwals et al.
patent: 7348002 (2008-03-01), Cosgrove
patent: WO 99/61040 (1999-12-01), None
patent: WO 99/61040 (2000-01-01), None
Abraham et al., “A monoclonal antibody to α1β1 blocks antigen-induced airway responses in sheep,” Jan. 1, 2004.American Journal of Respiratory Critical Care Medicine169(1):97-104.
Adams et al., “Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence,” Sep. 28, 1995.Nature377(6547 Suppl.):3-174.
Andreasen et al., “Expression and functional importance of collagen-binding integrins, α1β1 and α2β1, on virus-activated T cells,” 2003The Journal of Immunology171:2804-2811.
Bank et al., “Lymphocytes expressing α1β1 integrin (very late antigen-1) in peripheral blood of patients with arthritis are a subset of CD45RO+T-Cells primed for rapid adhesion to collagen IV,” Dec. 2002.Clinical Immunology105(3):247-258.
Border et al., “Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1,” Jul. 26, 1990.Nature346:371-374.
Branch, “A good antisense molecule is hard to find,” Feb. 1998.Trends in Biochemical Science23(2):45-50.
Conti and DiGioacchino, “MCP-1 and RANTES are mediators of acute and chronic inflammation,” May-Jun. 2001.Allergy and Asthma Proc.22(3):133-137.
Cook et al., “Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis,” Oct. 2002.American Journal of Pathology161(4):1265-1272.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 1RO1DK055000-01 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2003 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=2746599&p—grant—num=1R01DK055000-01&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 5RO1DK055000-02 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2003 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6177814&p—grant—num=5R01DK055000-02&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 5RO1DK055000-03 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2003 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6381443&p—grant—num=5R01DK055000-03&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 5RO1DK055000-04 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2003 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6517555&p—grant—num=5R01DK055000-04&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 2RO1DK055000-05A3 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2009 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6968892&p—grant—num=2R01DK055000-05A3&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 5RO1DK055000-06 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2009 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=7118099&p—grant—num=5R01DK055000-06&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove, Dominic; “Molecular aspects of Alport renal disease progression,” Grant Abstract, Grant No. 5R0IDK055000-07 [online]. National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Project dates Apr. 15, 1999 to Mar. 31, 2003 [retrieved on May 2, 2008]. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=7248757&p—grant—num=5R01DK055000-07&p—query=&ticket=63510999&p—audit—session—id=319533758&p—keywords=>; 2 pgs.
Cosgrove et al., “Integrin α1β1 and transforming growth factor-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy,” Nov. 2000.American Journal of Pathology157(5):1649-1659.
Cotran et al. (Eds), “Chapter 3: Acute and chronic inflammation,” inRobbins Pathologic Basis of Disease. W.B. Saunders Company: Philadelphia, PA; 1999. Title page, publishers page, table of contents, and pp. 50-88.
De Fougerolles et al., “Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis,” Mar. 2000.The Journal of Clinical Investigation105(6):721-729.
Dennis et al., “α1β1 Integrin Facilitates Monocyte Migration into the Tubulointerstitial Space of Fibrotic Kidneys in Murine Model of Alport's Syndrome,” Meeting Abstract. Poster No. SU-P0347, American Society of Nephrology (ASN) 35th Annual Meeting & Scientific Exposition. Pennsylvania Convention Center:—Philadelphia, PA. Nov. 1-3, 2002.
Dennis and Cosgrove, “Collagen XIII is induced on endothelial cells and may mediate VLA 1-dependent monocyte efflux in chronic renal fibrosis” Meeting Abstract. Abstract #329.39. FASEB Meeting on Experimental Biology: Translating the Genome 2004 Conference: Washington, DC. Apr. 17-21, 2004.
Fields et al., “Chapter 3: Principles and Practice of Solid-Phase Peptide Synthesis,” inSynthetic Peptides: A User's Guide. Grant (ed.). W.M. Freeman & Company, New York, NY:1992. Title page, publishers page and pp. 77-183.
Gardner et al., “Deletion of integrin α1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion,” 1996.Developmental Biology175:301-3

Affiliated with

Also associated with

Rating

Inducible ligand for &#x3b1;1&#x3b2;1 integrin and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inducible ligand for &#x3b1;1&#x3b2;1 integrin and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducible ligand for &#x3b1;1&#x3b2;1 integrin and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229053